AAV Integration Roundtable

August 18, 2021 | 8 a.m.-3 p.m. (CT)

View This Event in Your Time Zone

Adeno-associated virus (AAV) vectors are currently used to develop a wide range of therapies for many conditions given their ability to effectively transduce various cell types to produce long-term expression of transgenes. AAV vectors are known to deliver transgenes via in vivo gene delivery to support long-term expression.  While some vectors (e.g., gammaretrovirus, lentivirus, foamy virus etc.) are known to be integrating, other vectors such as AAV, have been historically understood to result in low levels of integration.  Although AAV vector genomes can persist within cells as episomes, varying reports from pre-clinical research suggest that more research is necessary to better understand the integration profile. The risk of rAAV-mediated oncogenesis in humans is theoretical, with no confirmed genotoxic events reported to date. However, there is a need to further understand and contextualize this phenomenon to inform further research, regulatory needs, and patient care. 

Jump to Registration


Co-Chairs: Kevin Eggan, Ph.D. and Douglas McCarthy, Ph.D. 

  • 8:00 am – 8:05 am: Beverly Davidson, Ph.D.: Opening Remarks: ASGCT's Involvement in AAV Integration

  • 8:05 am – 8:20 am: Kevin Eggan, Ph.D.: Introduction and Background  

8:20 am –11:05 am: Reflections from Nonclinical Data 

  • 8:20 am – 8:40 am: Mark Kay, M.D., Ph.D.: Characterizing AAV Integration 

  • 8:40 am – 9:00 am: Randy Chandler, Ph.D.: Rodent Study Results  

9:00 am – 9:15 am: Break 

  • 9:15 am – 9:35 am: Denise Sabatino, Ph.D.: Dog Study Findings 

  • 9:35 am – 9:55 am: David Lillicrap, M.D.: Dog Study Findings 

  • 9:55 am – 10:15 am: Irene Gil-Farina, Ph.D.: In Vitro Model Systems:

10:15 am – 11:00 am: Roundtable Discussion: Nonclinical Safety and Risk Assessment*

  • Moderator:  Douglas McCarthy, Ph.D. 

11:00 am – 11:50 am: Lunch Break 

11:50 am – 12:50 pm: Clinical Considerations: Best Practices for Risk Assessment 

  • 11:50 am – 12:10 pm: Approaches and Reflections Based on Past Experiences (e.g., adenovirus, retrovirus, etc.) 

  • 12:10 pm – 12:30 pm: Ricardo Dolmetsch, Ph.D.: uniQure Approach to Assessing Recent Data 

  • 12:30 pm – 12:50 pm: TBD 

12:50-1:35 pm: Roundtable Discussion: Clinical Considerations: Best Practices for Risk Assessment* 

  • Moderator: Kevin Eggan, Ph.D.

1:35 pm—1:50 pm: Break 

1:50 pm – 2:35 pm: Roundtable Discussion to Align on Next Steps: Post-Approval Considerations and Best Practices for AAV Integration Risk and Safety Assessment* 

*Roundtable Expert Participants:

  • Fred Bushman, Ph.D. 

  • Randy Chandler, Ph.D. 

  • Ricardo Dolmetsch, Ph.D. 

  • Irene Gil-Farina, Ph.D.

  • Markus Grompe, M.D.

  • Mark Kay, MD, Ph.D.

  • David Lillicrap, M.D.

  • Denise Sabatino, Ph.D. 


Are you an ASGCT Member?*:


Thank You to Our Sponsor


ASGCT Policy Summit

September 22-24, 2021

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.